Language:

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

PLoS medicine, 2006-09, Vol.3 (9), p.e356-e356 [Peer Reviewed Journal]

COPYRIGHT 2006 Public Library of Science ;COPYRIGHT 2006 Public Library of Science ;2006 Hogg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, et al. (2006) Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART. PLoS Med 3(9): e356. doi:10.1371/journal.pmed.0030356 ;2006 Hogg et al. 2006 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.0030356 ;PMID: 16984218

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
Author: Hogg, Robert S ; Bangsberg, David R ; Lima, Viviane D ; Alexander, Chris ; Bonner, Simon ; Yip, Benita ; Wood, Evan ; Dong, Winnie W Y ; Montaner, Julio S G ; Harrigan, P Richard
Lane, H. Clifford
Subjects: Adult ; Analysis ; Antiretroviral Therapy, Highly Active ; CD4 Lymphocyte Count ; Drug resistance ; Drug Resistance, Viral - genetics ; Drugs and adverse drug reactions ; Epidemiology ; Epidemiology/Public Health ; Female ; Follow-Up Studies ; Genotype ; Highly active antiretroviral therapy ; HIV Infection/AIDS ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - mortality ; HIV Infections - virology ; HIV Protease - genetics ; HIV Protease - metabolism ; HIV Protease Inhibitors - pharmacology ; HIV Protease Inhibitors - therapeutic use ; HIV Reverse Transcriptase - antagonists & inhibitors ; HIV Reverse Transcriptase - genetics ; HIV Reverse Transcriptase - metabolism ; HIV-1 - drug effects ; HIV-1 - enzymology ; HIV-1 - genetics ; HIV/AIDS ; Humans ; Infectious Diseases ; Male ; Molecular Sequence Data ; Mutation ; Patient outcomes ; Pharmacology/Drug Discovery ; Proportional Hazards Models ; Prospective Studies ; Reverse Transcriptase Inhibitors - pharmacology ; Reverse Transcriptase Inhibitors - therapeutic use ; RNA, Viral - blood ; RNA, Viral - genetics ; Survival Analysis ; Treatment Outcome ; Viral Load ; Virology
Is Part Of: PLoS medicine, 2006-09, Vol.3 (9), p.e356-e356
Description: The impact of the emergence of drug-resistance mutations on mortality is not well characterized in antiretroviral-naïve patients first starting highly active antiretroviral therapy (HAART). Patients may be able to sustain immunologic function with resistant virus, and there is limited evidence that reduced sensitivity to antiretrovirals leads to rapid disease progression or death. We undertook the present analysis to characterize the determinants of mortality in a prospective cohort study with a median of nearly 5 y of follow-up. The objective of this study was to determine the impact of the emergence of drug-resistance mutations on survival among persons initiating HAART. Participants were antiretroviral therapy naïve at entry and initiated triple combination antiretroviral therapy between August 1, 1996, and September 30, 1999. Marginal structural modeling was used to address potential confounding between time-dependent variables in the Cox proportional hazard regression models. In this analysis resistance to any class of drug was considered as a binary time-dependent exposure to the risk of death, controlling for the effect of other time-dependent confounders. We also considered each separate class of mutation as a binary time-dependent exposure, while controlling for the presence/absence of other mutations. A total of 207 deaths were identified among 1,138 participants over the follow-up period, with an all cause mortality rate of 18.2%. Among the 679 patients with HIV-drug-resistance genotyping done before initiating HAART, HIV-drug resistance to any class was observed in 53 (7.8%) of the patients. During follow-up, HIV-drug resistance to any class was observed in 302 (26.5%) participants. Emergence of any resistance was associated with mortality (hazard ratio: 1.75 [95% confidence interval: 1.27, 2.43]). When we considered each class of resistance separately, persons who exhibited resistance to non-nucleoside reverse transcriptase inhibitors had the highest risk: mortality rates were 3.02 times higher (95% confidence interval: 1.99, 4.57) for these patients than for those who did not exhibit this type of resistance. We demonstrated that emergence of resistance to non-nucleoside reverse transcriptase inhibitors was associated with a greater risk of subsequent death than was emergence of protease inhibitor resistance. Future research is needed to identify the particular subpopulations of men and women at greatest risk and to elucidate the impact of resistance over a longer follow-up period.
Publisher: United States: Public Library of Science
Language: English
Identifier: ISSN: 1549-1676
ISSN: 1549-1277
EISSN: 1549-1676
DOI: 10.1371/journal.pmed.0030356
PMID: 16984218
Source: GFMER Free Medical Journals
MEDLINE
PubMed Central
Public Library of Science (PLoS)
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

Searching Remote Databases, Please Wait